Quick Answer
CASI Pharmaceuticals, Inc. reported R&D Expense of $8.92 million for fiscal year 2024.
CASI Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $8.92M | -9.6% |
| 2023 | $9.86M | -38.4% |
| 2022 | $16.00M | — |
- CASI Pharmaceuticals, Inc. showed a decrease of -9.6% in R&D Expense compared to the prior fiscal year.
- Over the 2022–2024 period, CASI Pharmaceuticals, Inc.’s r&d expense has declined by 44.3% (from $16.00 million to $8.92 million).
- The most recent figure is from CASI Pharmaceuticals, Inc.’s fiscal year 2024 report (Form 20-F), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: